BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35

Benzinga · 2d ago
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.